髄膜炎ワクチン市場：タイプ別、ブランド別、血清型別、販売チャネル別、地域別

髄膜炎ワクチンの世界市場は、2025年には39億7,000万米ドルと推定され、2032年には63億米ドルに達し、2025年から2032年にかけてCAGR6.8％で成長すると予測されます。

図.髄膜炎ワクチン市場シェア（%）、2025年地域別

髄膜炎は、髄膜として知られる脳と脊髄を覆う保護膜の致死的な炎症です。髄膜炎は、細菌、ウイルス、寄生虫、真菌など様々な病原体によって引き起こされます。髄膜炎の最も一般的な原因はウイルス感染と細菌感染です。髄膜炎菌（Neisseria meningitidis）、肺炎球菌（Streptococcus pneumoniae）、インフルエンザ菌（Haemophilus influenzae type b）などによる細菌感染は、適切な抗生物質で速やかに治療しなければ、急速に重症化し、死に至ることさえあります。抗生物質による適時の治療で細菌性髄膜炎のほとんどの症例は治癒するが、それでも10～15％の症例で難聴、神経発達遅延、てんかんや四肢切断などの長期的な障害を引き起こす可能性があります。髄膜炎菌による侵襲性髄膜炎菌性疾患の発生を予防するためには、ワクチン接種が推奨されます。髄膜炎菌結合型ワクチンは、直接的な防御と集団免疫の両方を提供し、地域社会内での疾病の蔓延を効果的に抑制するために開発されました。

市場力学

髄膜炎ワクチンの世界市場成長は、主に侵襲性髄膜炎菌感染症による負担の増加と、世界の大規模予防接種プログラムの実施によってもたらされます。例えば、世界保健機関（WHO）が2021年に発表したデータによると、髄膜炎は年間約25万～50万人の患者を引き起こし、3万人以上が死亡しており、公衆衛生上の優先事項となっています。アウトブレイクを引き起こす一般的な病原性血清群の疫学が進化していること、各国の規制機関による定期的な予防接種の推奨、混合ワクチンの入手が可能であることなどが、予測期間中に市場に力強い成長機会をもたらすと予想されます。しかし、新規ワクチンの製造・開発に伴う高コスト、アウトブレイク時のワクチン在庫切れ、中低所得国における認識不足といった要因が、市場開拓の妨げになる可能性があります。新興血清型をカバーする手ごろな価格の多価ワクチンの開発と発展途上国における予防接種プログラムの拡大は、プレーヤーが参入し市場をさらに拡大するための有利な機会を提供します。

本調査の主な特徴

本レポートでは、世界の髄膜炎ワクチン市場を詳細に分析し、2024年を基準年とした予測期間（2025-2032年）の市場規模および複合年間成長率（CAGR%）を掲載しています。

また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。

また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。

世界の髄膜炎ワクチン市場における主要企業プロファイルを、企業ハイライト、製品ポートフォリオ、主要ハイライト、業績、戦略などのパラメータに基づいて掲載しています。

本レポートから得られる洞察により、マーケティング担当者や各企業の経営陣は、将来の製品上市、タイプアップ、市場拡大、マーケティング戦術に関して、十分な情報に基づいた意思決定を行うことができます。

髄膜炎ワクチンの世界市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー

第3章 市場力学、規制、動向分析

• 市場力学
• 影響分析
• 主なハイライト
• 規制シナリオ
• 製品の発売/承認
• PEST分析
• PORTERの分析
• 合併と買収のシナリオ
• 疫学

第4章 髄膜炎ワクチン市場、タイプ別、2020年～2032年、（10億米ドル）

• 二価
• 四価
• その他

第5章 髄膜炎ワクチン市場、ブランド別、2020年-2032年、（10億米ドル）

• メンクアッドフィ
• メンベオ
• トルメンバ
• ベクセロ
• その他

第6章 髄膜炎ワクチン市場、年齢グループ別、2020年～2032年、（10億米ドル）

• 乳児
• 大人

第7章 髄膜炎ワクチン市場、血清型別、2020年～2032年、（10億米ドル）

• 血清型A
• 血清型B
• 血清型C
• 血清型W-135
• その他

第8章 髄膜炎ワクチン市場、販売チャネル別、2020年～2032年、（10億米ドル）

• 民間
• 公共

第9章 髄膜炎ワクチン市場、地域別、2020年-2032年、（10億米ドル）

• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第10章 競合情勢

• Pfizer Inc.
• Sanofi
• GSK plc.
• Serum Institute of India Ltd.
• Merck & co., Inc.
• Walvax Biotechnology Co., Ltd.
• Icepta Pharmaceuticals Ltd.
• Hualan Biological Engineering Inc.

第11章 アナリストの推奨事項

• 機会
• アナリストの見解
• Coherent Opportunity Map

第12章 参考文献と調査手法

• 参考文献
• 調査手法
• 出版社について

Global Meningitis Vaccines Market is estimated to be valued at USD 3.97 Bn in 2025 and is expected to reach USD 6.30 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.8% from 2025 to 2032.

Figure. Meningitis Vaccines Market Share (%), By Region 2025

Meningitis is a potentially fatal inflammation of the protective membranes covering the brain and spinal cord known as meninges. It can be caused by various pathogens such as bacteria, viruses, parasites, and fungi. The most common causes of meningitis are viral and bacterial infections. Bacterial infections including those caused by Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type b can rapidly lead to serious illness and even death if not treated promptly with appropriate antibiotics. While timely treatment with antibiotics can cure most cases of bacterial meningitis, the infection may still lead to long-term disability in 10-15% of cases such as hearing loss, neurodevelopmental delay, and epilepsy or limb amputations. To prevent the occurrence of invasive meningococcal disease caused by N. meningitidis, vaccination is recommended. Meningococcal conjugate vaccines have been created to provide both direct protection and herd immunity, effectively controlling the spread of the disease within communities.

Market Dynamics

Global meningitis vaccines market growth is primarily driven by increasing burden of invasive meningococcal disease and implementation of large-scale immunization programs worldwide. For instance, as per the data published by the World Health Organization (WHO) in 2021, meningitis causes approximately 250,000-500,000 cases annually resulting in over 30,000 deaths, making it a public health priority. Evolving epidemiology of common pathogenic serogroups causing outbreaks, recommendations for routine immunization by national regulatory bodies and availability of vaccine combinations are expected to create robust growth opportunities in the market during the forecast period. However, factors such as high costs associated with the manufacturing and development of novel vaccines, vaccine stockouts during outbreaks, and lack of awareness in low and middle-income countries can hamper the market growth. Development of affordable multivalent vaccines covering emerging serotypes and expansion of immunization programs in developing nations present lucrative opportunities for player engagement and further market expansion.

Key Features of the Study

This report provides in-depth analysis of the global meningitis vaccines market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global meningitis vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer Inc., Sanofi, GSK plc., Serum Institute of India Ltd., Merck & co., Inc., Walvax Biotechnology Co., Ltd., Icepta Pharmaceuticals Ltd., and Hualan Biological Engineering Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global meningitis vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Market Segmentation

• Type Insights
  • Bivalent
  • Quadrivalent
  • Others
• Brand Insights
  • MenQuadfi
  • Menveo
  • Trumenba
  • Bexsero
  • Others
• Age Group Insights
  • Infants
  • Adults
• Serotype Insights
  • Serotype A
  • Serotype B
  • Serotype C
  • Serotype W-135
  • Others
• Sales Channel Insights
  • Private
  • Public
• Regional Insights
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Pfizer Inc.
  • Sanofi
  • GSK plc.
  • Serum Institute of India Ltd.
  • Merck & co., Inc.
  • Walvax Biotechnology Co., Ltd.
  • Icepta Pharmaceuticals Ltd.
  • Hualan Biological Engineering Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Meningitis Vaccines Market, By Type
  • Meningitis Vaccines Market, By Brand
  • Meningitis Vaccines Market, By Age Group
  • Meningitis Vaccines Market, By Serotype
  • Meningitis Vaccines Market, By Sales Channel
  • Meningitis Vaccines Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Epidemiology

4. Meningitis Vaccines Market, By Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Bivalent
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Quadrivalent
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Meningitis Vaccines Market, By Brand, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• MenQuadfi
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Menveo
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Trumenba
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Bexsero
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Meningitis Vaccines Market, By Age Group, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Infants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Adults
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Meningitis Vaccines Market, By Serotype, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Serotype A
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Serotype B
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Serotype C
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Serotype W-135
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Meningitis Vaccines Market, By Sales Channel, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Private
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Public
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Meningitis Vaccines Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Brand, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Serotype, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Sales Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, Country, 2020 - 2032, (USD Bn)
  • U.S.
  • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Brand, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Serotype, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Sales Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, Country, 2020 - 2032, (USD Bn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Brand, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Serotype, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Sales Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, Country, 2020 - 2032, (USD Bn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Brand, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Serotype, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Sales Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, Country, 2020 - 2032, (USD Bn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Brand, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Serotype, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Sales Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, Country, 2020 - 2032, (USD Bn)
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Brand, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Serotype, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, By Sales Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, Country/Region, 2020 - 2032, (USD Bn)
  • South Africa
  • North Africa
  • Central Africa

10. Competitive Landscape

• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GSK plc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Serum Institute of India Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Walvax Biotechnology Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Icepta Pharmaceuticals Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Hualan Biological Engineering Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us